Partnership Opportunities with the Frederick National Laboratory

Size: px

Start display at page:

Download "Partnership Opportunities with the Frederick National Laboratory"

Brian Shaw
5 years ago
Views:

Partnership Opportunities with the Frederick National Laboratory Vladimir Popov

Instruments in Our Backyard - Baltimore Core Facilities - May 2018 DEPARTMENT

Institute Frederick National Laboratory is a Federally Funded Research and

1 Partnership Opportunities with the Frederick National Laboratory Vladimir Popov Business Development Manager Partnership Development Office Expertise and Instruments in Our Backyard - Baltimore Core Facilities - May 2018 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute Frederick National Laboratory is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute

Frederick National Laboratory - history 1971.

Signed the National Cancer Act creating the National Cancer Program. 1972.

2 Frederick National Laboratory - history President Nixon transferred 68 acres of military property to Health and Human Services. Signed the National Cancer Act creating the National Cancer Program Frederick Cancer Research and Development Center was established on the 68 acres FFRDC designation made Frederick National Laboratory for Cancer Research was designated as a federal national laboratory. The most significant action taken in this Administration.

3 Relationship with NCI Located on NCI s Frederick, Maryland, campus Frederick National Laboratory

4 Budget FY 2017 allocation by major source Total Other Institutes/Agencies 4% Total NIAID- VRC 27% Total NCI 69%

discovery and innovation in the biomedical sciences, focusing on cancer, AIDS,

computational science molecular characterization basic, translational, and

5 Why partners seek the FNL? The Frederick National Laboratory is dedicated to improving human health through discovery and innovation in the biomedical sciences, focusing on cancer, AIDS, and emerging infectious diseases. What does the FNL do? computational science molecular characterization basic, translational, and clinical science cancer, HIV/AIDS, and cancer viruses nanotechnology characterization and formulations animal models and animal imaging biomedical imaging electron microscopy

local start-ups to global pharmaceutical companies

6 Who are our partners? Who partners with the FNL? 127 collaborating institutions Partners range from local start-ups to global pharmaceutical companies Many partners have multiple collaborations with us.

7 Value of commercial partnerships Benefits to Partners Benefits to FNL/NCI Benefits to Cancer/HIV Patients Access to specialized equipment and unique capabilities Access to national laboratory expertise Proof-of-concept assistance Long-term ability to grow with partners SBIR/STTR proposal cooperation Enhance the FNL/NCI mission via supporting additional biomedical research Collaborate around cutting-edge drugs and technologies More high-quality research driving improved cancer, HIV/AIDS, and cancer virus therapies

8 Partnership mechanisms ccrada & mccrada Collaboratio n Agreement MTA Beta-Testing Research Plan Data Publishing Provisions IP and Licensing Opportunities Confidentiality Incoming Funds Material Exchange Collaborative Research

9 Partnership mechanisms: Technical Service Agreements (TSAs) TSAs offer easy access to some of FNL s unique services and solutions. Each service has a set fee, and the TSA can be negotiated quickly (~1 week). Currently, 21 services are available, including: Viral load analysis cdna Synthesis/Single Genome Amplification KRAS/p53 mouse models and cell lines for PDAC and NSCLC 1,520 mouse embryonic cell lines with most known mouse mirnas Nanomedicine pharmacokinetics in rats Nanomedicine drug release study in human plasma HLA genotyping Expression profiling for human B-cell lymphoma on the NanoString platform HIV/SIV Services Lab Animal Services Nanomedicines & Formulation Other Services

10 Collaboration case study: Local biotechs Visited local business incubators Connected with small biomedical and biotech companies, including: Small clinical-stage biotech New start-up Introduced companies to FNL investigators in the Laboratory Animal Sciences Program Signed an MTA for the evaluation of one of the company s flagship formulations in cancer mouse models Signed a Collaboration Agreement for the evaluation of an immunotherapy platform in cancer mouse models Research is underway!

11 frederick.cancer.gov Vladimir Popov, PhD Business Dev. #FredNatLab

Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies

Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies Colin Duckett, Ph.D. Professor, Departments of Pathology & Internal Medicine Director,